Developing a Cure for HIV
Raised to Date: Raised: $265,300
Aggregate Commitments $
Rolling Commitments $
Are you, or is someone you know, impacted by the devastating effects of HIV? With 1,800,000 people living with it each year, chances are you answered yes. If so, then investing in BioClonetics might be for you. They’ve created an antibody that can both target and neutralize the HIV virus, meaning that a safer and more effective treatment for HIV now exists.
BioClonetics is on a mission to develop a cure for HIV...and they’re well their way to making it a reality. They’ve created a proprietary cell line that produces an anti-HIV antibody called CLone 3. They’ve demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates, and their validating tests were conducted at four prestigious US laboratories and one Austrian one (including Harvard Medical School and Duke University). They expect to complete animal trials in the next 24 months, and they have several world-class laboratories who will assist them in those next phases. BioClonetics treatment differs from current treatments in that it is non-toxic, does not require lifetime treatment, and is much more affordable. Plus, it’s effective -- so far it’s been proven to work 100% against over 92% of all strains and viral subtypes of HIV-1.
The Bottom Line:
HIV is still one of the top causes of death worldwide. About 57% of people infected with HIV have no treatment, while the treatment the other 43% receives, antiretroviral drugs, is both toxic and expensive. BioClonetics is non-toxic, more affordable, and can help prevent HIV from spreading in the first place. In fact, with BioClonetics, we might just be able to fight HIV -- and even end it all together.
Upgrade to gain access
- Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- , plus
- Company specific
- Advanced company search ( )
- Get Edge Annual
- Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- In-depth risk ratings for every raise
- Get Edge Pro Annual